Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4621 - PRORADIUM: Prospective MultiCentre Study of Prognostic Factors in Castration Resistant Prostate Cancer (CRPC) patients Treated with Radium-223


10 Sep 2017


Poster display session


Surgical Oncology;  Radiation Oncology;  Prostate Cancer


Rafael Morales Barrera


Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370


R. Morales Barrera1, M.I. Sáez2, N. Romero-Laorden3, R. Lozano Mejorada4, D. Lorente Estelles5, G. de Velasco6, M.A. Gonzalez Del Alba Baamonde7, E. Gonzalez Billalabeitia8, A. Medina9, P. Borrega García10, A. Rodriguez-Vida11, U. Ferrandiz Brotons12, O. Fernandez Calvo13, R. García Domínguez14, J. Puente15, J.M. Piulats Rodriguez16, R. Villatoro17, E. Castro Marcos18, D. Olmos Hidalgo19

Author affiliations

  • 1 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 2 Medical Oncology, H Universitario Virgen de la Victoria y Regional de Málaga, Malaga/ES
  • 3 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, 28029 - Madrid/ES
  • 4 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid/ES
  • 5 Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia/ES
  • 6 Medical Oncology, Hospital Univesitario 12 de Octubre, Madrid/ES
  • 7 Medical Oncology, Hospital Universitario Son Espases, 7010 - Palma de Mallorca/ES
  • 8 Medical Oncology Department, Hospital Universitario Morales Meseguer, 30008 - Murcia/ES
  • 9 Medical Oncology, Centro Oncológico de Galicia, A Coruña/ES
  • 10 Medical Oncology, H. San Pedro de Alcántara, Cáceres/ES
  • 11 Medical Oncology, University Hospital del Mar, 8003 - Barcelona/ES
  • 12 Medical Oncology, Instituo Catalán de Oncología (ICO), Badalona/ES
  • 13 Medical Oncology, Complejo Hospitalario Universitario de Ourense, Ourense/ES
  • 14 Medical Oncology, Hospital Universitario de Salamanca, 37007 - Salamanca/ES
  • 15 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 16 Medical Oncology, Insitut Catalán d'Oncología, 8907 - Barcelona/ES
  • 17 Medical Oncology, Hospital Costa del Sol, Málaga/ES
  • 18 Prostate Cancer Unit, CNIO- Spanish National Cancer Center, 28029 - Madrid/ES
  • 19 Prostate Cancer Clinical Cancer Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid/ES


Abstract 4621


Several new agents have been approved for CRPC, but we are still so far from being able to predict which group of patients might benefit from a particular strategy. Therefore, the identification of new predictive and prognostic biomarkers is urgently needed. In this setting, bone metabolism markers (BMM) assume particular importance regarding to R223.

Trial design

PRORADIUM is a prospective multicentre observational study in metastatic CRPC designed to explore biomarkers in patients treated with R223. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with R223. Primary end point: to validate the prognostic value for overall survival (OS) of serum BMM expression described by Primo N Lara et al (JNCI 2014). Secondary end points: a) to analyse the prognostic role for PSA response regarding to BMM expression; b) to correlate radiological response with BMM; c) to investigate the association of skeletal related events with BMM; d) to analyse the prognostic role of alkaline phosphatase before and during R223; e) to analyse the prognostic value of “Bone Scan Index” in response evaluation; f) to analyse the prognostic role for OS of AR-V7 and AR amplification; g) to validate the prognostic role of the expression signature described by Olmos et al (Lancet Oncol 2012) in peripheral blood. Exploratory outcomes: a) to validate prognostic nomograms described for CRPC; b) to explore new somatic and germinal variants in peripheral blood and tissue associated to response and resistance to R223. PRORADIUM is part of the PROCURE Biomarkers network, a multicentric spanish platform for biomarkers discovery in CRPC patients. 161 patients will be accrued to provide appropriate statistical power to detect at least 85 events (deaths) to analyse the main outcome. Currently, 48 centres are active for recruitment and 54 patients have been included. Blood samples are collected before, during and after progression to R223. Prospective data collection will be linked. This study may help to incorporate new biomarkers in clinical practice and improve the selection of therapy in mCRPC.

Clinical trial identification


Legal entity responsible for the study

Spanish National Cancer Research Centre (CNIO)


Bayer Hispania, S.L


A. Medina: Honoraria from Bayer Hispania, S.L. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.